The BMP-2 mutant L51P: a BMP receptor IA binding-deficient inhibitor of noggin

被引：0
作者：
Hany Mohamed Khattab
Satoshi Kubota
Masaharu Takigawa
Takuo Kuboki
Walter Sebald
机构：
[1] Fayoum University,Department of Prosthodontics, Faculty of Oral and Dental Medicine
[2] Okayama University Graduate School of Medicine,Advanced Research Center for Oral and Craniofacial Sciences
[3] Dentistry and Pharmaceutical Sciences,Department of Biochemistry and Molecular Dentistry
[4] Okayama University Graduate School of Medicine,Department of Oral Rehabilitation and Regenerative Medicine
[5] Dentistry and Pharmaceutical Sciences,Physiological Chemistry II
[6] Okayama University Graduate School of Medicine,undefined
[7] Dentistry and Pharmaceutical Sciences,undefined
[8] Theodor-Boveri-Institute for Biocenter of Würzburg University,undefined
来源：
Journal of Bone and Mineral Metabolism | 2019年 / 37卷
关键词：
BMP-2; BMP antagonist; L51P; BMP negative feedback;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The antagonist-specific regulation in tissue engineering constitutes important attempts to achieve an improved and rapid bone regeneration by controlling the natural biological response of the natural body growth factors. L51P is molecularly engineered bone morphogentic protein-2 (BMP-2) variant with a substitution of the 51st leucine with a proline residue. L51P is deficient in BMP receptor binding, but maintains its structure and affinity for inhibitory proteins such as noggin, chordin, and gremlin. These modifications convert the BMP-2 variant L51P into a receptor-inactive inhibitor of BMP antagonists. This current approach may prevent the uncontrolled bone overgrowth using high concentration of BMPs and thus regulates the possible growth factor’s high-dose side effects. Exploring of L51P biological functions is required to broad our understanding of BMP mutant biological functions and their potential clinical applications. The progress of L51P researches would hopefully lead to the development of multiple applications for using the L51P in bone and fracture healing disorders.
引用
收藏
页码：199 / 205
页数：6
相关论文
共 324 条
  • [1] Sieber C(2009)Recent advances in BMP receptor signaling (in eng) Cytokine Growth Factor Rev 20 343-355
  • [2] Kopf J(2013)WNT signaling in bone homeostasis and disease: from human mutations to treatments (in eng) Nat Med 19 179-192
  • [3] Hiepen C(2013)Expression and functional study of extracellular BMP antagonists during the morphogenesis of the digits and their associated connective tissues (in eng) PLoS One 8 e60423-317
  • [4] Knaus P(2005)BMP antagonists: their roles in development and involvement in pathophysiology (in eng) Cytokine Growth Factor Rev 16 309-3078
  • [5] Baron R(2009)Levels of expression for BMP-7 and several BMP antagonists may play an integral role in a fracture nonunion: a pilot study (in eng) Clin Orthop Relat Res 467 3071-1399
  • [6] Kneissel M(2011)High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo (in eng) Tissue Eng Part A 17 1389-137
  • [7] Lorda-Diez CI(2009)Targeting bone morphogenetic protein antagonists: in vitro and in vivo evidence of their role in bone metabolism (in eng) Expert Opin Ther Targets 13 123-488
  • [8] Montero JA(2004)Molecular recognition of BMP-2 and BMP receptor IA (in eng) Nat Struct Mol Biol 11 481-710
  • [9] Rodriguez-Leon J(2004)Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction (in eng) Biol Chem 385 697-954
  • [10] Garcia-Porrero JA(2005)Bone morphogenetic protein signalling and vertebrate nervous system development (in eng) Nat Rev Neurosci 6 945-491
12345678910